Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial
- DOI
- 10.1016/j.eclinm.2023.102123
- Published
- 2023-08
- Container
- eClinicalMedicine
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.eclinm.2023.102123,
title = {Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial},
author = {Xuefeng Fang and Ning Zhu and Chenhan Zhong and Liuhong Wang and Jun Li and Shanshan Weng and Hanguang Hu and Caixia Dong and Dan Li and Yongmao Song and Dong Xu and Jianwei Wang and Lifeng Sun and Jian Wang and Zhanhuai Wang and Hongfeng Cao and Xiujun Liao and Ningjuan Yu and Qian Xiao and Mi Mi and Suzhan Zhang and Kefeng Ding and Ying Yuan},
year = {2023},
journal = {eClinicalMedicine},
doi = {10.1016/j.eclinm.2023.102123},
url = {https://doi.org/10.1016/j.eclinm.2023.102123}
}RIS
TY - JOUR TI - Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial AU - Xuefeng Fang AU - Ning Zhu AU - Chenhan Zhong AU - Liuhong Wang AU - Jun Li AU - Shanshan Weng AU - Hanguang Hu AU - Caixia Dong AU - Dan Li AU - Yongmao Song AU - Dong Xu AU - Jianwei Wang AU - Lifeng Sun AU - Jian Wang AU - Zhanhuai Wang AU - Hongfeng Cao AU - Xiujun Liao AU - Ningjuan Yu AU - Qian Xiao AU - Mi Mi AU - Suzhan Zhang AU - Kefeng Ding AU - Ying Yuan PY - 2023 JO - eClinicalMedicine DO - 10.1016/j.eclinm.2023.102123 UR - https://doi.org/10.1016/j.eclinm.2023.102123 ER -
APA
Fang, X., Zhu, N., Zhong, C., Wang, L., Li, J., Weng, S., Hu, H., Dong, C., Li, D., Song, Y., Xu, D., Wang, J., Sun, L., Wang, J., Wang, Z., Cao, H., Liao, X., Yu, N., Xiao, Q., Mi, M., Zhang, S., Ding, K., & Yuan, Y. (2023). Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial. eClinicalMedicine. https://doi.org/10.1016/j.eclinm.2023.102123
Source records
- crossref · retrieved 2026-09-26T05:22:40.325Z